Roche's RoActemra gets EU approval for RA
This article was originally published in Scrip
Executive Summary
Roche's first-in-class rheumatoid arthritis drug RoActemra (tocilizumab) has been approved by theEuropean Commission, and Roche plans to work with the regulators in EU member countries to make the drug available as quickly as possible.